Health Catalyst stock rating reiterated at Overweight by Cantor Fitzgerald

Investing.com - Cantor Fitzgerald has reiterated an Overweight rating on Health Catalyst Inc. (NASDAQ:HCAT) with a price target of $9.00, representing significant upside from the current price of $3.89. According to InvestingPro data, analysts’ targets range from $4.00 to $10.00, with the company currently appearing undervalued based on Fair Value analysis.

The research firm expressed optimism about Health Catalyst’s sales pipeline remaining on track through 2025, noting several positive signals extending into 2026.

Cantor Fitzgerald pointed to survey results showing a shift toward positive sentiment regarding longer-term ROI products, while also noting that policy-related bear cases appear to be diminishing.

Early indicators for 2026 were described as encouraging for both revenue and profit outlook, which could suggest positive management commentary during upcoming selling seasons.

Health Catalyst provides data and analytics technology and services to healthcare organizations, helping them improve clinical, financial, and operational outcomes. The company maintains a moderate debt level with a current ratio of 1.24, indicating adequate liquidity to meet short-term obligations.

In other recent news, Health Catalyst Inc. has been at the center of several significant developments. The company held its annual meeting where shareholders approved all proposals, including the election of two directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm. Meanwhile, BTIG downgraded Health Catalyst from Buy to Neutral, citing concerns over potential reductions in healthcare coverage and market saturation, alongside a deceleration in revenue growth. Stifel maintained a Hold rating on Health Catalyst, noting the company’s ambitious revenue and EBITDA targets for 2025 amid various challenges. Canaccord Genuity adjusted its price target to $9 while maintaining a Buy rating, highlighting the company’s affirmation of business performance metrics and its commitment to organic growth. Evercore ISI increased the price target for Health Catalyst to $5, emphasizing the company’s efforts to expand its Total (EPA:TTEF) Addressable Market through the Ignite platform. These recent developments reflect a mix of strategic moves and analyst perspectives as Health Catalyst navigates its growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.